{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial on Pain Management in Minimally Invasive Cardiac Surgery"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "This randomised controlled trial aimed to evaluate the efficacy of pain management strategies in MICS."
      },
      "Participants": {
        "score": 2,
        "evidence": "Participants were eligible if they were undergoing MICS and were recruited from a single cardiac surgery center."
      },
      "Intervention": {
        "score": 2,
        "evidence": "The intervention group received thoracic epidural analgesia (TEA), while the control group received thoracic paravertebral block (TPVB)."
      },
      "Objective": {
        "score": 1,
        "evidence": "This randomised controlled trial aimed to evaluate the efficacy of pain management strategies in MICS."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was postoperative pain measured on a visual analog scale (VAS) over 48 hours."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was computer-generated, and allocation was concealed using sealed envelopes."
      },
      "Blinding": {
        "score": 3,
        "evidence": "Blinding was applied to outcome assessors, patients, and clinicians."
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "A total of 200 participants were randomised: 100 to the TEA group and 100 to the TPVB group, between January 2020 and June 2021."
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "Analysis was conducted on 98 participants in the TEA group and 97 in the TPVB group using an intention-to-treat approach."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "The mean VAS score was significantly lower in the TEA group (mean difference = 1.5, 95% CI 0.8 to 2.2; p < 0.001)."
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events occurred in 5% of the TEA group and 3% of the TPVB group, with no severe complications reported."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NCT12345678"
      },
      "Funding": {
        "score": 1,
        "evidence": "This trial was funded by the National Institute of Health."
      }
    },
    "total_score": 25,
    "max_score": 25
  },
  "model": "gpt-4o"
}